Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
didaxini
- Development stage
- Unknown
- Lead developer
- Jingxin Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Didaxini (also known as EVT-201) is a small molecule partial positive allosteric modulator (PAM) of the GABA-A receptor, specifically targeting the benzodiazepine binding site. Developed by Zhejiang Jingxin Pharmaceutical under license from Evotec, it is indicated for the treatment of insomnia. Unlike traditional full-agonist benzodiazepines or non-benzodiazepine "Z-drugs" (such as zolpidem), didaxini's partial agonism is designed to provide sufficient sedative-hypnotic efficacy while reducing the incidence of common side effects such as residual next-day sedation, cognitive impairment, motor incoordination, and the potential for tolerance or dependence. The drug received approval from China's National Medical Products Administration (NMPA) in 2023, making it a novel therapeutic option for patients with sleep onset and maintenance difficulties.
- Brand names
- Didaxini
- Other names
- 地达西尼Didaxini Capsules
02
Targets
GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)Gamma-aminobutyric acid type A receptor, benzodiazepine site (α2/α3/α5-containing subtypes)
Beyond the preview
Go deeper on didaxini.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on didaxini.